Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Drug-Drug Interaction Study to Investigate the Effect of Givosiran on the Pharmacokinetics (PK) of Midazolam, Caffeine, Losartan, Omeprazole, and Dextromethorphan in Patients With Acute Intermittent Porphyria (AIP) Who Are Asymptomatic High Excreters (ASHE)

Trial Profile

A Drug-Drug Interaction Study to Investigate the Effect of Givosiran on the Pharmacokinetics (PK) of Midazolam, Caffeine, Losartan, Omeprazole, and Dextromethorphan in Patients With Acute Intermittent Porphyria (AIP) Who Are Asymptomatic High Excreters (ASHE)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Givosiran (Primary) ; Caffeine; Dextromethorphan; Losartan; Midazolam; Omeprazole
  • Indications Acute intermittent porphyria
  • Focus Pharmacokinetics
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2021 Results effect of givosiran on the activity of five major CYP enzymes, that together metabolize approximately 80% of clinically used drugs (19), in subjects with AIP who have biochemically active disease but do not experience acute attacks, published in the Clinical Pharmacology and Therapeutics.
    • 14 Aug 2019 According to an Alnylam Pharmaceuticals media release, results from this study will be presented at the 2019 International Congress on Porphyrins and Porphyria (ICPP).
    • 05 Feb 2019 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top